4-Methylsulfonylbenzylamine → HCID 58614647, compound
Reaction equation
[Cl:1][C:2]1[CH:3]=[C:4]([CH:8]=[CH:9][C:10]=1[C:11](=[O:26])[NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)[C:5](O)=[O:6].[CH3:27][S:28]([C:31]1[CH:36]=[CH:35][C:34]([CH2:37][NH2:38])=[CH:33][CH:32]=1)(=[O:30])=[O:29]>>[Cl:1][C:2]1[CH:3]=[C:4]([C:5]([NH:38][CH2:37][C:34]2[CH:33]=[CH:32][C:31]([S:28]([CH3:27])(=[O:30])=[O:29])=[CH:36][CH:35]=2)=[O:6])[CH:8]=[CH:9][C:10]=1[C:11]([NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)=[O:26]Participants
3
Procedure
62 mg of 3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid was coupled to (4-(methylsulfonyl)phenyl)methanamine via Procedure G. The crude product was purified on reverse phase HPLC to yield 2-chloro-N1-(4-chloro-3-(pyridin-2-yl)phenyl)-N4-(4-(methylsulfonyl)benzyl)terephthalamide. MS (Q1) 554 (M)+.
Workup
- customThe crude product was purified on reverse phase HPLC
Sources & evidence
- ORD record
- ord-3798234b69e84026964e27f1f17b6029
- Source dataset
- uspto-grants-2016_04
- Patent number
- US09321761B2
Reaction notes
Loading…